Share Name Share Symbol Market Type Share ISIN Share Description
Genuit Group Plc LSE:GEN London Ordinary Share GB00BKRC5K31 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  -4.00 -1.05% 375.50 176,964 16:35:14
Bid Price Offer Price High Price Low Price Open Price
376.00 377.00 383.50 373.50 381.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Industrial Engineering 594.30 62.90 16.70 22.5 932
Last Trade Time Trade Type Trade Size Trade Price Currency
17:55:13 O 5,489 381.134 GBX

Genuit (GEN) Latest News (1)

More Genuit News
Genuit Investors    Genuit Takeover Rumours

Genuit (GEN) Discussions and Chat

Genuit Forums and Chat

Date Time Title Posts
17/3/202210:31Genuit Group53
19/11/200619:49GEN - SILLY PRICE500
26/8/200405:32Watching closely-
07/8/200314:33Anyone here invested in Generics?3
10/4/200217:16Further gloom for Generics UK4

Add a New Thread

Genuit (GEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-07-04 16:55:20381.135,48920,920.45O
2022-07-04 16:44:37375.502,5139,436.32O
2022-07-04 16:19:42381.008413,204.18O
2022-07-04 16:14:29375.502,74910,322.50O
2022-07-04 16:05:58379.06234886.99O
View all Genuit trades in real-time

Genuit (GEN) Top Chat Posts

Genuit Daily Update: Genuit Group Plc is listed in the Industrial Engineering sector of the London Stock Exchange with ticker GEN. The last closing price for Genuit was 379.50p.
Genuit Group Plc has a 4 week average price of 370p and a 12 week average price of 370p.
The 1 year high share price is 805p while the 1 year low share price is currently 370p.
There are currently 248,169,282 shares in issue and the average daily traded volume is 298,958 shares. The market capitalisation of Genuit Group Plc is £931,875,653.91.
km18: ...from last year... Company overview: Genuit Group is actually the new name of Polypipe Group plc. They provide sustainable solutions for water, climate and ventilation management. Sustainability is at the core of the firm’s strategy, driven by constant innovations. Genuit benefits from the active plans of governments across the globe to achieve net zero strategies and promote ESG activities and foresees geographic reach to be a major driver of growth for the group in the long term. Blended approach for growth, with several acquisitions and continuous Capex seems to be working for the company in the long run, as both revenues and EPS have been growing steadily over the past 6 years, with the sole exception the catharsis of 2020. Fundamentally the company is also supported by a solid history of debt retirement and cash generation. the half-year report sounds very promising. The group revenue was 32.5% above the 2019 figure (yes, that is a 3rd above the covid free year), driven by a significant raise in residential business at £183.8m (64% growth yoy lfl basis). The sole red flag on the report comes in the face of pressured margins, coming from the rising input costs. This has been balanced very nicely by 8% increase in prices for final customers, which proves the company’s brand recognition.  The labour supply issues several sectors are experiencing seems to be fading at Genuit, but we suggest keeping your eyes open for September for further guidance on the direction of the “pingdemic”. Genuit’s exposure to pen air projects is what supported the performance during the lockdowns, but the group saw drop in the commercial side of the sector. So, overall growth there is mediocre at 8.3%. Analyst consensus is expecting 9% increase in profit, built on the residentials and the acquisitions which are performing quite well. The board is expecting “underlying operating profit for FY to be ahead of expectations”....from WealthOracleAM
scooper72: Looks like Aberdeen Standard Investments who hold 10.96 percent have cut their holding by about 10 percent and sold 2.3M shares last month. And I guess there must be others with large holding taking some profits. I'm now down an annoying 14 percent on my current holding in my SIPP having sold out previously at 688p with my original larger holding in my ISA. But thinking it is a bit late to comfortably take the £300 loss without worrying about doubly kicking myself if the price recovers. Today's drop seems hard to understand when considering the results out this morning looked ok
dope007: Input costs are definitely not past their peak. Additionally the industry is seeing further raw material shortage issues. Order books are full but at some point these horrendous input price rises are going to lead to reducing orders. However Genuit are in a better place than the window boys with less reliance on the home replacement mkt were at some point a home owner is going to say nope, not paying that...
scooper72: Do you see these factors averaging out in terms of when they announce their profits or do you see the share price pulling back further on results whenever they come out. Ok kicking myself for going back in a bit early and just wondering where fair value is currently.
dope007: Like the rest of our industry 2 dynamics are at play 1) Raw mat massive price hikes and ongoing/rolling shortages 2) High demand so selling everything they can produce even at higher prices
philanderer: Yesterday's Deutsche note.. (Sharecast News) - Analysts at Deutsche Bank raised their target price on plastic piping manufacturer Genuit from 653.0p to 708.0p on Wednesday, citing the group's "strong" first-half performance Deutsche Bank pointed to Genuit's adjusted interim operating profit of £48.6m, eclipsing its 2019 first-half performance by roughly 24% as it primary reason for the upgrade but also noted that the company appeared to be continuing to trade well, prompting a rise in management's expectations for the full year. "We raise our 2021-2023E operating profit forecasts by 4-7% and our target price by circa 8%," said the German bank, which also reiterated its 'buy' rating on the stock. "The company remains a strong performer, with recent acquisitions operating at or above expectations (three in February alone indicative of a team that does not let the grass grow under its feet)."
philanderer: Keyno, it seems to be bouncing back. Maybe helped by this? Genuit Group: Deutsche Bank keeps at buy and raises target price from 653.0p to 708.0p.
philanderer: Genuit Group: Berenberg reiterates hold with a target price of 630p.
rambutan2: we hold a small stake (see header)... Nanoscience Like many smaller AIM-listed investment vehicles, Nanoscience is playing a high stakes poker game where a real result from just one of its venture-backed biotechnology subsidiaries could send its share price soaring. Nanoscience listed on Aim last March, and is trading at 8.50p, from a high of around 17p last year. However, experts are particularly impressed by the potential for one of its investments – Imperial College spin-out Toumaz Technology Limited, which is developing a revolutionary vital signs monitoring system for patients. If tests in the first quarter of next year are successful, Toumaz will produce a battery-powered vital signs monitor, so tiny patients will be able to wear it in a bandage or plaster, that will continuously transmit back to doctors for five days. Nanoscience paid £17.1m for Toumaz, raising an additional £7.1m in development funding, helping to push it to a pre-tax loss of £2.5m in the six months to 29th September. The AIM vehicle has made a series of other acquisitions including a 2.9 per cent stake in Swedish gas sensing development company Applied Sensor Sweden. Presenting its interim results the company promised a "period of continuing and rapid evolution towards commercialisation". Buy.
ariane: Interim Results RNS Number:5593Q Generics Group AG 30 August 2005 30 August 2005 THE GENERICS GROUP AG ('GENERICS') INTERIM RESULTS 2005 Generics, a leading integrated technology consulting, development and investment organisation, today announces its results for the six months to 30 June 2005. Highlights: * Turnover increased by 28% to #10.7m (H1 2004: #8.3m) * Consulting and IP exploitation activities reported operating profit of #0.3m (H1 2004 loss of #0.1m) while increasing fee income by 34% * Operating loss for the Group of #0.9m (H1 2004 loss of #2.1m) after expensed costs of spinouts of #0.6m * Portfolio BVCA valuation of #12.5m (Q1 2005: #11.9m) * Cash balance of #3.6m (Q4 2004: #5.1m) before proceeds of #1.05m from the disposal of Imerge Ltd * Generics' spinout CMR Fuel Cells Ltd received the 2005 Carbon Trust award as Innovator of the year and in addition was a winner of the Individual and Small Business of the Year category * Successful completions of #4m financing by Sphere Medical Holding Ltd, originally Generics' medical device joint venture with Siemens, and #2.3m financing by CMR Fuel Cells Ltd * Launch of SGAI Tech Ltd, Scientific Generics' Hong Kong based joint venture * Adjusted losses per share of 0.5 pence (2004 loss of 1.0 pence) * Net assets per share of 8.7p per share (H1 2004: 9.4p) before taking into account the BVCA portfolio valuation uplift equivalent to 3.5p per share (H1 2004: 3.0p) On 11 August 2005 Generics announced that it had completed the sale of its shareholding in Imerge Limited. The consideration included a cash payment of #1.05m, and future incentive payments dependent upon performance. The BVCA valuation for Generics' share of Imerge at Q1 2005 was #1.3m. Johan Bjorklund, Generics' Chairman, commented: "I am pleased with both the development of the group during the first six months and the progress in the consulting and IP exploitation activities in particular. Our core technology development and consulting activity grew significantly, increasing fee income by 34% year-on-year whilst achieving a good and increasing profitability. SGAI Tech, our Hong Kong based joint venture, is performing ahead of forecast, adding new clients to its initial customer, Hornby plc. Income from licensing and royalty activities will improve with the next AutosheathTM milestone payment of $0.5m expected in the second half. While Q3 is likely to see a moderate seasonal reduction in revenue and sales run-rate, the order book and sales processes are now strong enough to sustain the ongoing growth in the technology consulting and IP business. Within our venturing activity during the first half we have received industry accolades for our spinout companies, CMR Fuel Cells Ltd and Sphere Medical Holding Ltd, both of which have been successfully financed in the year to date. Various funding, IPO and disposal opportunities continue to be developed across the portfolio. The prospects for CMR and Sphere, in particular, are strong." Enquiries: The Generics Group AG (44) 1223 875200 Martin Frost Simon Davey
Genuit share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220704 23:55:28